Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
STOCKHOLM, SVERIGE 14 mars 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardios grundare, professor Lars Lund, har publicerat en studie inom hjärtsvikt...
-
STOCKHOLM, SWEDEN March 14, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the founder of its portfolio company AnaCardio, Professor Lars Lund, has published an article...
-
STOCKHOLM, SVERIGE 13 mars 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Biosergen presenterat positiva resultat från en klinisk fas 1-studie med...
-
STOCKHOLM, Sweden, March 13, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen has presented positive results from a clinical phase 1 study of its...
-
STOCKHOLM, SVERIGE 28 februari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines, tidigare Svenska Vaccinfabriken Produktion AB, har inlett en...
-
STOCKHOLM, Sweden, February 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines, formerly Svenska Vaccinfabriken Produktion AB, has initiated...
-
STOCKHOLM, SVERIGE 28 februari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics har tagit in finansiering genom en garanterad nyemission...
-
STOCKHOLM, SWEDEN, February 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has closed an underwritten public offering of USD 5.5...
-
STOCKHOLM, SVERIGE 21 februari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics presenterat positiva resultat från bolagets kliniska fas...
-
STOCKHOLM, SWEDEN February 21, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has presented positive results from the company’s...